Post by mitchellreed on Aug 20, 2016 14:31:43 GMT -6
Biotech takeout targets:
PGNX, ACAD SYGP JUNO CLDX
I am long PGNX....ramping sales tons of cash:
Valeant Pharmaceuticals International Inc.’s Relistor drug has attracted interest from other companies as the beleaguered Canadian firm works to reduce its debt load, people familiar with the matter said. A potential sale could value the constipation treatment at $400 million to $500 million, the people said, asking not to be identified because the deliberations are private. Valeant could still choose not to sell the drug, the people said. A representative for Valeant declined to comment. Chief Executive Officer Joe Papa is seeking to ease a debt burden that ballooned to more than $30 billion as he also works to help the business recover from criticism of its business practices and drug pricing. Valeant and its partner for Relistor, Progenics Pharmaceuticals Inc., said last month that the U.S. Food and Drug Administration approved the tablet form of the drug to treat constipation brought on by taking opioids for chronic, non-cancer pain. Valeant said it expects to start selling Relistor tablets in the U.S. in the third quarter this year. An injectable form of the treatment was approved by the FDA in 2008. Progenics said on July 26 it had received a $50 million payment from Valeant after the FDA’s approval. Progenics is entitled to receive as much as $200 million of milestone payments tied to sales of the drug, the company said.
PGNX acquisition could be a fit for a company with the right distribution channels who was looking to buy own Relistor and not have to pay PGNX another 200 million in milestone payments.
Needham Summer Preview-We have 4 companies under coverage with drugs under FDA review this year: ACAD (BUY)-Nuplazid approved 4/29. Launch Q2. ICPT (BUY)-Ocaliva approved 5/27. Launch June Cempra (BUY)-Solithera PDUFA 12/27-28 Lexicon (BUY)-Telotristat PDUFA 11/30
I don't know them all well enough to have an opinion. Took positions in ACAD and RPTP for reasons in my posts. I avoided DEPO after a quick look. I've been in UTHR in the past but nothing for past several months.
Under: DIS finally getting some traction.?
Dec 14, 2017 17:08:45 GMT -6
martyc: I took an entry level position in DIS. Will add eventually to overweight when it becomes clearer that the deal will go thru. Can't believe how well positioned they will be. 60% Hulu. 20% of content watched on NFLX they can pull. More in thread
Dec 14, 2017 11:05:16 GMT -6
Under: Great posts on $DIS
Dec 13, 2017 17:50:49 GMT -6
Under: $ROKU Citron on a war path.
Nov 28, 2017 15:11:20 GMT -6
Under: $HAS takeover bid for $MAT?
Nov 10, 2017 16:16:07 GMT -6
martyc: Not looking like the market will provide any discounted opp for SGMO. Call was just too professional and all signs indicate they are on a great path for commercialization. Happy with core but wish I had some trading shs
Nov 10, 2017 9:04:05 GMT -6
martyc: For anyone looking to find an entry point into SGMO, I'm almost hoping is sells off in next few days so I can add more. They are really clicking but the fact they haven't signed new deals might cause some to exit. Watching as I have room for trading shs
Nov 9, 2017 18:28:09 GMT -6
martyc: Been an interesting ride so far. I figured the Bears would be about this good but hoped the O wouldn't look so lame. Another building yr but still possible to get to 8-8 IMO
Nov 9, 2017 18:26:08 GMT -6
Under: whats up with your Bears this year Marty?
Nov 9, 2017 17:35:25 GMT -6
martyc: Hope you were long ROKU. I wanted to see Q first so missed out
Nov 9, 2017 7:08:53 GMT -6